Table I.
Baseline demographics and characteristics
| Characteristic | Placebo (n = 90) | Upadacitinib 15 mg (n = 91) | Upadacitinib 30 mg (n = 91) |
|---|---|---|---|
| Female, n (%) | 16 (17.8) | 23 (25.3) | 22 (24.2) |
| Age (y), mean (SD) | 36.3 (12.6) | 35.9 (13.2) | 34.7 (12.7) |
| Age group (y), n (%) | |||
| Adolescents (<18) | 9 (10.0) | 10 (11.0) | 10 (11.0) |
| Adults (≥18) | 81 (90.0) | 81 (89.0) | 81 (89.0) |
| Weight (kg), mean (SD) | 67.6 (12.8) | 65.1 (14.2) | 66.2 (14.4) |
| BSA (%), mean (SD) | 62.0 (20.5) | 61.7 (23.7) | 66.7 (21.2) |
| Disease duration since diagnosis (y), mean (SD) | 24.7 (14.4) | 23.0 (14.3) | 20.7 (14.1) |
| hs-CRP (mg/L), mean (SD) | 3.1 (6.4) | 2.3 (3.8) | 3.9 (8.8) |
| vIGA-AD, n (%) | |||
| Moderate (score < 4) | 47 (52.2) | 47 (51.6) | 48 (52.7) |
| Severe (score = 4) | 43 (47.8) | 44 (48.4) | 43 (47.3) |
| EASI, mean (SD) | 34.4 (13.0) | 34.2 (14.1) | 36.1 (14.5) |
| Worst Pruritus NRS, mean (SD) | 6.8 (1.3) | 6.7 (1.4) | 7.0 (1.4) |
| Medical history, n (%) | |||
| Asthma | 34 (37.8) | 29 (31.9) | 28 (30.8) |
| Rhinitis allergic | 58 (64.4) | 45 (49.5) | 45 (19.5) |
| Conjunctivitis allergic | 11 (12.2) | 8 (8.8) | 12 (13.2) |
BSA, Body surface area; EASI, Eczema Area and Severity Index; hs-CRP, high-sensitivity C-reactive protein; NRS, numerical rating scale; vIGA-AD, validated Investigator's Global Assessment for Atopic Dermatitis.